PDCD1 and cancer: Favorable clinical outcomes have been reported for various cancers treated with antibodies targeting PD-1, PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), prompting increased interest in cancer immunology [21,22].